Kirsten Castillo net worth and biography

Kirsten Castillo Biography and Net Worth

Director of Ocugen

Ms. Castillo has over 20 years of supply chain and logistics experience, having held multiple supply chain leadership roles at a spin-off company of 3M, where she led multiple major acquisitions and integrations for the company. During her tenure at Logistics Planning Services, a privately held transportation and logistics services company, where she served as CEO, the company achieved aggressive growth plans which ultimately resulted in the sale of the business to GlobalTranz, a strategic buyer in the 3PL sector. She stayed on through the transition as Chief Operating Officer and was responsible for all company operations including regional branches in North America and Mexico, delivering $1.6B in revenue before stepping down to pursue new opportunities.

Ms Castillo is committed to the advancement of women and has been named the Vice President of Engagement for AWESOME (Advancing Women’s Excellence in Supply Chain, Operations, Management and Education). She serves on the Boards of The Marvin Companies and the United Way (UWWCE), and serves on the Advisory Board of Fuqua’s Center for Entrepreneurship and Innovation at Duke University. She received her BS from the University of Minnesota, her Global Executive MBA from Duke Fuqua School of Business and has additional education including a Lean Office Certification from the University of Michigan Engineering Program, six sigma training and Carson School of Management executive training on Mergers and Acquisitions.

What is Kirsten Castillo's net worth?: The estimated net worth of Kirsten Castillo is at least $8,486.02 as of June 6th, 2024. Ms. Castillo owns 9,239 shares of Ocugen stock worth more than $8,486 as of November 21st. This net worth evaluation does not reflect any other assets that Ms. Castillo may own. Learn More about Kirsten Castillo's net worth.
How do I contact Kirsten Castillo?: The corporate mailing address for Ms. Castillo and other Ocugen executives is 5 GREAT VALLEY PARKWAY V, MALVERN PA, 19355. Ocugen can also be reached via phone at (484) 328-4701 and via email at [email protected]. Learn More on Kirsten Castillo's contact information.
Has Kirsten Castillo been buying or selling shares of Ocugen?: Kirsten Castillo has not been actively trading shares of Ocugen over the course of the past ninety days. Most recently, Kirsten Castillo sold 42,000 shares of the business's stock in a transaction on Thursday, August 11th. The shares were sold at an average price of $2.91, for a transaction totalling $122,220.00. Following the completion of the sale, the director now directly owns 50,000 shares of the company's stock, valued at $145,500. Learn More on Kirsten Castillo's trading history.
Who are Ocugen's active insiders?: Ocugen's insider roster includes Kirsten Castillo (Director), Prabhavathi Fernandes (Director), Uday Kompella (Director), Ramesh Kumar (Director), Shankar Musunuri (CEO), Manish Potti (Director), Sanjay Subramanian (CFO), Vijay Tammara (SVP), and Junge Zhang (Director). Learn More on Ocugen's active insiders.

Kirsten Castillo Insider Trading History at Ocugen

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/11/2022	Sell	42,000	$2.91	$122,220.00	50,000
6/7/2021	Sell	10,000	$10.00	$100,000.00	65,000
5/28/2020	Buy	75,000	$0.31	$23,250.00	75,000

Kirsten Castillo Buying and Selling Activity at Ocugen

Ocugen Company Overview

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.

Today's Range

Now: $0.92

$0.85

$0.94

50 Day Range

MA: $1.00

$0.87

$1.23

2 Week Range

Now: $0.92

$0.36

$2.11

Volume

4,352,756 shs

Average Volume

4,200,968 shs

Market Capitalization

$267.58 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

3.75

[625,000% Gain] – Are You Ready for the Next Altcoin Boom?

From Crypto Swap Profits | Ad

All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.